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To describe clinical aspects of pandemic (H1N1) 2009 
virus–associated pneumonia in children, we studied 80 such 
children, including 17 (21%) with complications, who were 
admitted to 5 hospitals in Japan during August–November 
2009 after a mean of 2.9 symptomatic days. All enrolled 
patients recovered (median hospitalization 6 days). Timely 
access to hospitals may have contributed to favorable out-
comes.
W
e describe the clinical aspects of pandemic (H1N1) 
2009 virus infection in children who developed 
spontaneous pneumomediastinum (1) or plastic bronchi-
tis (2). In Mexico, 18 persons, including 5 children, had 
pandemic (H1N1) 2009–associated pneumonia (3). How-
ever, active surveillance to collect data on pneumonia cases 
among children infected with pandemic (H1N1) 2009 virus 
has not been conducted in Japan. 
The Study
Active procurement of specimens from pediatric inpa-
tients with pandemic (H1N1) 2009–associated pneumonia 
was organized by the Laboratory of Molecular Epidemiol-
ogy for Infectious Agents at Kitasato University. Clinical 
data and respiratory specimens were provided by pediatric 
departments at 5 institutions during August 9–November 6, 
2009. Pandemic (H1N1) 2009–associated pneumonia was 
diagnosed from inﬂ   uenza-like illnesses associated with 
inﬁ  ltrates on chest radiographs and laboratory-conﬁ  rmed 
pandemic (H1N1) 2009 virus (3). Each patient’s pediatri-
cian informed us of any major complication that followed 
the pneumonia.
First, patients were divided into 2 groups: those who 
had and did not have complications. The group having no 
complications then was divided into 2 age-deﬁ  ned sub-
groups (cutoff, 6 years). Each subgroup was further divided 
into subgroups: hospital admission 1–3 days after symptom 
onset or admission >4 days after symptom onset. Informa-
tion about clinical features; routine laboratory ﬁ  ndings at 
hospital admission; and if available, serum immunoglobu-
lin E concentration was obtained from patients’ medical 
charts. Tachypnea was deﬁ  ned by using criteria in Japanese 
guidelines adopted in 2007 for managing respiratory infec-
tious diseases (4) in children. Chest radiographic ﬁ  ndings 
taken at time of hospital admission were classiﬁ  ed by ex-
tent of pulmonary inﬁ  ltrates (localized vs. diffuse) and in-
ﬁ  ltrate distribution (bilateral vs. unilateral; upper, middle, 
or lower lung ﬁ  eld) (4).
Nasopharyngeal swabs (n = 79) or an endotracheal as-
pirate were sent to the laboratory for microbiologic iden-
tiﬁ  cation. Pandemic (H1N1) 2009 virus in specimens was 
determined by real-time reverse transcription–PCR (RT-
PCR) (1,2). Additionally, comprehensive real-time RT-
PCR was performed to conﬁ  rm respiratory co-infection 
with any of 12 viruses (5). Multiplex real-time PCR also 
was performed to detect 6 respiratory bacteria (6).
Patient demographic characteristics, symptoms, physi-
cal ﬁ  ndings, treatments, and clinical courses were com-
pared between groups with and without complications by 
using the χ2 test. Neutrophil and lymphocyte counts were 
analyzed by using box-and-whisker plots. A p value <0.05 
indicated a signiﬁ  cant difference between patient groups.
The study comprised 80 pediatric inpatients who re-
ceived treatment at 5 medical institutions for pandemic 
(H1N1) 2009–associated pneumonia over a 3-month pe-
riod. Family members were informed about the purpose of 
the study, and children’s parents provided informed con-
sent.
We compared patients by presence or absence of com-
plications (Table 1). Complications included pleural effu-
sion (5 patients), pneumomediastinum (6), atelectasis (6), 
myositis (2), and plastic bronchitis (1). No patients had or-
gan dysfunction or encephalopathy.
The median age of pneumonia patients was 7 years; 57 
(71%) were male; 26 (33%) had asthma, 4 (5%) had atopic 
dermatitis without asthma, and 1 (1%) had DiGeorge syn-
drome. Forty-nine (61%) patients were previously healthy. 
Mean time from onset of illness to admission was 2.9 
days; 61 (76%) patients were admitted early to the hospital 
(within 3 days after symptom onset). Respiratory distress, 
inspiratory retraction, and low percutaneous oxygen satu-
ration (<93% while breathing room air) were signiﬁ  cantly 
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Inﬁ  ltrates were more often localized (64 patients) than 
diffuse (16 patients). Unilateral localized inﬁ  ltrates  oc-
curred more commonly in a lower lung ﬁ  eld than in upper 
or middle ﬁ  elds, and unilateral inﬁ  ltrates were more com-
mon in the right than left lung.
Clinical laboratory results are shown in Table 2. The 
neutrophil count was signiﬁ  cantly higher in patients with 
complications than in others (Figure 1). Lymphopenia 
(<1,000 cells/μL) was characteristic in children with com-
plications and in children who had no complications and 
were >6 years of age and admitted to the hospital on day 
1–3 of illness (Figure 2). Lymphocyte count was signiﬁ  -
cantly higher in the corresponding group with admission 
>4 days after onset. Serum immunoglobulin E concentra-
tion was high (>170 IU/mL) in both groups admitted on day 
1–3, regardless of whether complications were present.
PCR detected bacteria in nasopharyngeal specimens 
from 41 (51%) patients. Organisms present included Strep-
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Table 1. Demographic characteristics and clinical features of children hospitalized with pandemic (H1N1) 2009–associated 
pneumonia, Japan, August–November 2009* 
Variable Total
Group A, no complications, 
n = 63 
Group B, complications, 
n = 17 
p value, 
A vs. B 
Sex, M/F  57 (71.3)/23 (28.8)  46 (73.0)/17 (27.0)  11 (64.7)/6 (35.3)  0.71
Median age, y (range)  7 y (9 mo–14y)  7 y (9 mo–14 y)  6 y (4 y–12 y)  0.41
 < 1 y  4 (5)  4 (6.3)  0
  2–5 y  14 (17.5)  11 (17.5)  3 (17.6) 
 > 6 y  62 (77.5)  48 (76.2)  14 (82.3) 
History of asthma   26 (32.5)  21 (33.3)  5 (29.4)  0.76
Admission <3 d/>4 d after symptom onset  61 (76.3)/19 (23.8)  45 (71.4)/18 (28.6)  16 (94.1)/1 ( 5.9)  0.10
Major symptoms, physical findings 
  Cough   66 (82.5)  53 (84.1)  13 (76.5)  0.71
  Respiratory distress  29 (36.3)  17 (27.0)  12 (70.6)  <0.01
 Fever  >38°C  74 (92.5)  58 (92.1)  16 (94.1)  0.53
  Tachypnea  57 (71.3)  42 (66.6)  15 (88.2)  0.15
  Inspiratory retraction  39 (48.8)  27 (42.9)  12 (70.6)  0.04
  Rhonchi  48 (60.0)  40 (63.5)  8 (47.1)  0.22
   SpO2 <93  39 (48.8)  25 (39.7)  14 (82.4)  <0.01
Treatment and clinical course 
 O 2 supplementation  49 (61.3)  34 (54.0)  15 (88.2)  0.01
  Mean duration of O2 administration, d  
 (range) 
3.5 (1–11)  2.9 (1–6)  4.7 (1–11)  0.02
  Treatment with oseltamivir  67 (83.8)  51 (80.9)  16 (94.1)  0.35
  Treatment with antimicrobial drugs†  63 (78.8)  46 (73.0)  17 (100)  0.04
  Isoproterenol inhalation  6 (7.5)  0 6 (35.3)  <0.01
Median duration of hospitalization, d (range)   6 (3–18)  6 (3–9)  8 (5–18)  <0.01
*Values are no. (%) except as indicated. SpO2, percutaneous oxygen saturation while breathing room air. 
†Parenteral infusion of sulbuctum/ampicillin or cefazoin was carried out for 3–5 d. 
Table 2. Laboratory test results for children hospitalized with pandemic (H1N1) 2009–associated pneumonia, Japan, August–
November 2009* 
Characteristic 
Group A, no complications, n = 63  Group B, complications, n = 17 
Age <5 y, n = 15  Age >6 y, n = 48  Age >6 y, n = 14 
Leukocytes, cells/ȝL (range)†  6,400 (3,600–14,400)  7,400 (2,400–17,100)  14,200 (5,100–22,700) 
  Neutrophils‡  4,929 (2,227–8,256)  6,081(1,248–15,287)  12,849 (4,182–22,042) 
  Lymphocytes§  1,593 (74–7,638)  608 (214–2,064)  560 (295–1,889) 
  Eosinophils  0 (0–102)  16 (0–918)  23 (0–145) 
  Monocytes  240 (37–1,685)  359 (99–1,271)  337 (0–714) 
CRP, mg/dL (range)¶
   1.0 (0.1–2.9)  2.4 (0.05–11.95)  3.5 (1–7.83) 
LDH, IU/L (range)¶  304 (230–415)  248 (182–575)  248 (193–353) 
CK, IU/L (range)¶  101 (40–328)  110 (29–2,240)  148 (57–1,524) 
IgE, IU/mL (range)#
  61 (7.3–311)  443 (34–4,680)  1,058 (43–4,011) 
*CRP, C-reactive protein; LDH, lactate dehydrogenase; CK, creatine kinase; Ig, immunoglobulin. 
†Reference ranges by age group: <1 y, 7,000–15,000; 2–5 y, 7,000–11,000; >6 y, 6,500–10,000. 
‡Reference range by age group: <1 y, 4,000–8,000; 2–5 y, 2,500–5,500; >6 y, 3,000–5,000. 
§Reference range by age group: <1 y, 4,000–11,000; 2–5 y, 3,000–7,000; >6 y, 2,500–4,500. 
¶Reference upper limits for CRP, LDH, and CK levels are 0.3, 400, and 200, respectively. 
#Reference ranges for IgE by age group: 1–3 y, <30; 4–6 y, <110; >7 y, <170. Serum IgE data were analyzed when available.  Pandemic (H1N1) 2009–associated Pneumonia
tococcus pneumoniae (25 patients), Haemophilus inﬂ  uen-
zae (28), and Mycoplasma pneumoniae and S. pyogenes (1 
each); some patients had multiple organisms. In addition, 
rhinovirus was detected in 2 patients and enterovirus in 1.
Forty-nine (61%) patients required oxygen administra-
tion (mean duration 3.5 days) (Table 1). Oxygen supple-
mentation was provided signiﬁ  cantly more often to chil-
dren who had than who did not have complications (15 
[88%] vs. 34 [54%]; p<0.05). A total of 67 (84%) patients 
received oseltamivir, and 63 (79%) received antimicrobial 
drugs. Median time from onset of symptoms to initiation 
of oseltamivir treatment (4 mg/kg/d for 5 days) based on 
20 applicable patients was 2 days, showing no differences 
between groups. Isoproterenol inhalation was needed only 
for patients with complications. In 1 patient who had an 
asthma attack, plastic bronchitis developed and the patient 
required invasive mechanical ventilation for 5 days.
All children recovered, with a median hospital stay of 
6 days (Table 1). Hospitalization was longer for patients 
with than without complications (median 8 days vs. 6 days; 
p<0.01).
Our study has several limitations. Our PCR data from 
nasopharyngeal swabs cannot distinguish pathogens from 
colonizing organisms and cannot reliably guide decisions 
regarding antimicrobial drug treatment. Various reports 
have described invasive secondary bacterial infection with 
Staphylococcus aureus diagnosed from lower respiratory 
tract or blood specimens (7,8); such cultures were not 
obtained from all of the patients in our study. Moreover, 
pneumonia may have been underdiagnosed in our patients 
considering limited sensitivity of chest radiography com-
pared with computed tomography (9).
Conclusions
Pediatricians should be aware that early diagnosis of 
inﬂ  uenza can enable prompt antiviral treatment of severe 
illness. All Japanese citizens have ready access to medi-
cal institutions through the national health insurance sys-
tem. On November 13, 2009, the Japan Pediatric Society 
reported surveillance data concerning 60 pandemic (H1N1) 
2009–associated deaths in children (10). Main causes of 
death were sudden death and rapidly progressive severe 
pneumonia. Testing practices, access, and policies regard-
ing early administration of antiviral agents have protected 
many children from life-threatening pandemic (H1N1) 
2009.
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Figure 1. Neutrophil counts (cells/μL) in blood samples from 5 
groups: patients with complications, patients >6 years of age 
without complications who had early or late hospital admission, and 
patients <5 years of age without complications who had early or late 
hospital admission. Data were analyzed by using box-and-whisker 
plots. Lower limit, median, and upper limit shown within each box 
correspond to the 25%, 50%, and 75% percentile, respectively; 
half of the patients considered fall within each box. Dotted lines 
extending from each box represent 1.5× the quartile deviation. 
Open red circles, outlying cases; closed diamonds, medians; 
horizontal bars, means.
Figure 2. Lymphocyte counts (cells/μL) in blood samples from 5 
groups (patients with complications, patients >6 years of age 
without complications who had early or late hospital admission, and 
patients <5 years of age without complications who had early or 
late hospitalization). Data were analyzed by using box-and-whisker 
plots. Lower limit, median, and upper limit shown within each box 
correspond to the 25%, 50%, and 75% percentile, respectively; 
half of the patients considered fall within each box. Dotted lines 
extending from each box represent 1.5× the quartile deviation. 
Open red circles, outlying cases; closed diamonds, medians; 
horizontal bars, means.Dr Hasegawa is a fellow in the Department of General Pedi-
atrics, Nerima-Hikarigaoka Hospital, Nihon University School of 
Medicine, in Tokyo. His primary research interests focus on gen-
eral pediatric medicine; respiratory medicine, including asthma; 
and infectious diseases and clinical microbiology, particularly 
involving major respiratory tract pathogens.
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